While Pacira BioSciences Inc has underperformed by -1.51%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, PCRX fell by -12.20%, with highs and lows ranging from $31.67 to $11.16, whereas the simple moving average jumped by 25.57% in the last 200 days.
On January 30, 2025, Truist Upgraded Pacira BioSciences Inc (NASDAQ: PCRX) to Hold. A report published by Truist on August 13, 2024, Downgraded its rating to ‘Sell’ for PCRX. RBC Capital Mkts also Downgraded PCRX shares as ‘Sector Perform’, setting a target price of $14 on the company’s shares in a report dated August 12, 2024. Piper Sandler August 12, 2024d its ‘Overweight’ rating to ‘Neutral’ for PCRX, as published in its report on August 12, 2024. JP Morgan’s report from August 12, 2024 suggests a price prediction of $10 for PCRX shares, giving the stock a ‘Underweight’ rating. Barclays also rated the stock as ‘Equal Weight’.
Analysis of Pacira BioSciences Inc (PCRX)
Further, the quarter-over-quarter increase in sales is 2.83%, showing a positive trend in the upcoming months.
One of the most important indicators of Pacira BioSciences Inc’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. The goal here is to ensure that your current return on equity of -11.48% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 1.89, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and PCRX is recording 812.84K average volume. On a monthly basis, the volatility of the stock is set at 5.27%, whereas on a weekly basis, it is put at 4.44%, with a loss of -4.44% over the past seven days. Furthermore, long-term investors anticipate a median target price of $28.57, showing growth from the present price of $26.04, which can serve as yet another indication of whether PCRX is worth investing in or should be passed over.
How Do You Analyze Pacira BioSciences Inc Shares?
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 4.53%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 111.45% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
PCRX shares are owned by institutional investors to the tune of 111.45% at present.
